Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences
Bull Case

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

• Edwards Lifesciences Co. recently secured FDA approval for the AUTUS Size-Adjustable Valve, which is the first surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease, expanding the company's addressable market into a new demographic that previously lacked a one-time solution for valve replacement as they grow.
• The company demonstrated strong financial performance in its most recent quarterly report, beating consensus estimates with earnings per share of $0.78 compared to the expected $0.74 and generating revenue of $1.74 billion, which exceeded the $1.70 billion forecast, indicating robust demand for its structural heart disease therapies.
• Wall Street maintains a positive outlook on the stock, with an average rating of Moderate Buy from twenty-three analysts and an average target price of $100.27, suggesting that the current market valuation leaves room for significant upside potential as the company continues to execute on its growth strategy.
• Investors can benefit from the company's strategic expansion in transcatheter valve platforms, including the SAPIEN M3 mitral valve, which is part of a broader ambition to build a multibillion-dollar business in transcatheter mitral and tricuspid therapies by 2030, positioning the firm as a leader in minimally invasive cardiac procedures.
• The stock currently trades at $85.23, which is below the average analyst target price and offers a potential entry point for investors looking to capitalize on the company's recent product approvals and strong earnings momentum, particularly given that the fifty-two week high reached $96.29.